Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics presented real-world data at the 2026 ASCO Annual Meeting confirming that the SEZ6 protein is a highly expressed target for small cell lung cancer and other neuroendocrine tumors. These findings support the development of their antibody-drug conjugate, HWK-206, with an IND submission planned for mid-2026.
Why it matters
Advancements in targeted oncology therapies like ADCs offer potential breakthroughs for treating aggressive cancers with limited current options.
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
The content is a standard corporate press release regarding clinical research and development.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in